SOLICITATION NOTICE
66 -- ACEA CES2-16X with CIM Station
- Notice Date
- 9/6/2006
- Notice Type
- Solicitation Notice
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- Reference-Number-NCI-60194-NV
- Response Due
- 9/13/2006
- Archive Date
- 9/28/2006
- Description
- The National Cancer Institute (NCI), Center for Cancer Research (CCR), Laboratory of Pathology (LP) plans to enter into a sole source procurement for an ACEA CES2-16X with CIM Station ? PC controlled device for measurement of cell growth rates,viability, migration, adhesion, proliferation, morphology, invasion, chemotaxsis, differentiation, apoptosis, cytotoxicity, and cell activation GPCR activation, receptor tyrosine kinase activation, and cell transfection in label free cells on a real time basis from ACEA Biosciences, Inc., 11585 Sorrento Valle Road, Suite 103, San Diego, CA 92121-1310. The North American Industry Classification System Code is 334516 and the business size standard is 500 employees. This acquisition will be processed under FAR Part 12 ? Acquisition for Commercial Items and will be made pursuant to the authority in FAR 13.5 to use simplified procedures for commercial acquisitions. ACEA Biosystems is the only source known to the NCI researcher that has patented technology which allows the assaying on a small numbers of cells with consistent results which is required for their research and detailed below in their JOFOC. However, if any interested party believes it can perform requirement as detailed in the JOFOC they may submit a statement of capabilities. The statement of capabilities and any other furnished information must be in writing and must contain material in sufficient detail to allow the NCI researcher to determine if the party can perform this requirement. An original and one copy of the capability statement must be received in the contracting office by 1:00 pm EDT, on September 13, 2006. Faxed and emailed capability statements are NOT authorized. All questions must be in writing and may be emailed to Debbie Moore at dm170b@nih.gov or faxed (301) 402-4513. It is the vendor?s responsibility to call (301) 402-4509 and verify that questions were received. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award from the NCI contractors must be registered in the Online Representations and Certifications Applications (ORCA). Please refer to http://orca.bpn.gov in order to register. In addition, contractors must be registered in the Central Contractor Registration (CCR) www.ccr.gov. No collect calls will be accepted. JUSTIFICATION FOR OTHER THAN FULL AND OPEN COMPETITION Part I: Background information and Description of Acquisition Title: ACEA CES2-16X with CIM Station- a PC controlled device for Measurement of Cell growth, migration, adhesion, proliferation, viability, morphology, invasion, cell differentiation, chemotaxsis, cytotoxicity, apoptosis, and cell activation in label free cells on a real time basis over the course of the experiment(multiple data points not just an endpoint). It can also measure GPCR activation, receptor tyrosine kinase activation and cell transfection. Purpose/Brief History: The Lab of Pathology at the National Cancer Institute has a need to acquire an ACEA CES2-16X with CIMStation. This instrument is used to observe in real time and without radioactive labels several parameters of cell growth such as cell growth, migration, adhesion, proliferation, viability, morphology , invasion, cell differentiation, chemotaxsis, cytotoxicity, apoptosis, and cell activation. It can also measure GPCR activation, receptor tyrosine kinase activation, and cell transfection. The ACEA CES2-16X is able to do these assays on significantly smaller cell numbers of cells (5 to 10 times less) than the current technology which makes it more usable in many more assays that would employ primary cell lines harvested from transgenic mice which are very difficult to grow outside the animal. This ability to assay with far fewer cells (5,000 to 10,000 cells instead of needing 50,000 to 100,000 cells per treatment condition) is of paramount importance especially when testing transgenic mice since the sacrifice of one mouse is required for each 100,000 endothelial cells needed. . This instruments assays are much more stable and consistent because it has a module that fits inside the incubator where the cells are grown and can send info about cell changes as they grow and metabolize on a real time basis. It can send data about cell conditions at multiple points in time with only one experiment rather than needing several different time endpoints to determine desired data. Because of the uniform conditions inside the cell incubator this instrument gives better statistical reliability of assay data and more info about the cells over time. The LP believes that the acquisition of this equipment would allow them to do assays on cells previously unavailable in sufficient numbers to assay by older methods. It would also provide much more reliable data and in a much greater volume and faster time while sacrificing fewer animals than anything now available. PART II: Facts and reasons to Justify Other than Full and Open Competition Statutory authority FAR 13.106(b)(1) b) Soliciting from a single source. (1) For purchases not exceeding the simplified acquisition threshold, contracting officers may solicit from one source if the contracting officer determines that the circumstances of the contract action deem only one source reasonably available (e.g., urgency, exclusive licensing agreements, or industrial mobilization). Justification: As Stated above ACEA Biosciences is the only manufacturer of such an instrument which allows assays of various cellular functions on such small numbers of cells and provides such reliable consistency of results. This machine employs patented technology that allows these assays to be carried out on such small numbers of cells. The number of cells required for alternative techniques is a severe limitation on the types and amounts of tissues we can do these assays on and thus currently prevents certain experiments on transgenic mice altogether.
- Record
- SN01134713-W 20060908/060906220402 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |